Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD

Representative Image (AI-generated) A blood-cancer treatment that Stanford researchers have spent more than two decades developing has now reached an important milestone. Its first commercial patient has been treated following U.S. Food and Drug Administration approval. According to the Stanford Cancer Institute, the therapy, known as Orca-T, was given to a patient at Stanford Medicine outside a clinical trial. The treatment received FDA approval in June 2026 after a phase 3 trial found that 78% of patients receiving Orca-T were free from moderate-to-severe graft-versus-host disease (GVHD) one year after transplantation. Among patients who received a standard transplant, the figure was 38.4%.Why GVHD remains a concernFor people with blood cancers, a stem cell transplant can offer a chance to rebuild the blood and immune system with healthy cells from a donor. But the procedure also carries serious risks, including GVHD. The condition occurs when immune cells from the donor recognise the patient's tissues as foreign and begin attacking them. GVHD can affect different parts of the body and can become a significant complication following transplantation.At the same time, donor immune ...